Conflict of interest
Peter Hellings: Consultant and recipient of lecture fees and/or research grants from Sanofi, Regeneron, Novartis, GSK, ALK and Viatris.
Isam Alobid: Consultant for Sanofi, Novartis, AstraZeneca, GSK, Viatris, Salvat, Storz, Olympus, Metronic, MSD and Roche.
Wilma Anselmo Lima: No conflicts of interest to declare in relation to this initiative.
Manuel Bernal-Sprekelsen: Speaker honorarium from GSK Spain, Olympus Europe, Viatris Spain, Sanofi Spain. Editor-in-Chief Eur.Arch.ORL-HNS.
Leif Bjermer: Hourly fee for medical consultancy from Acucort, Airsonett, Astrazeneca, Birc and Phargentis. Lecture fees from AstraZeneca, GlaxoSmithKlein, Birc and Sanofi. Advisory board at AstraZeneca, GSK and Sanofi.
Lisa Caulley: No conflicts of interest to declare in relation to this initiative.
Adam Chaker: Dr. Chaker reports grants, speaker honoraria, consultancy or advisory fees and/or research support and other all via Technical University of Munich from Allergopharma, ALK Abello, Astra Zeneca, Bencard/Allergen Therapeutics, GSK, Novartis, LETI, Roche, Zeller, Sanofi Genzyme/Regeneron, Thermo Fisher, European Institute of Technology (EIT Health) and Federal Ministery of Research and Education Germany.
Jannis Constantinidis: Has received honoraria for consultancy from GSK.
Diego Conti: No conflicts of interest to declare in relation to this initiative.
Eugenio De Corso:  Received fee for consultation, speaker activity, advisory board by Sanofi, Regeneron, GSK, Novartis and Astrazeneca.
Martin Desrosiers: Received fee for consultation, speaker activity, advisory board by sanofi/Regeneron, GSK. Research support, sanofi/Regeneron, GSK.Equity holder, Probionase Therapies Inc.
Zuzana Diamant:In the past 3 years, ZD received speaker or consultant honoraria and/or served on advisory boards at: Antabio, Foresee Pharmaceuticals, GlaxoSmithKline, Hippo-Dx, QPS-Netherlands, Sanofi-Genzyme-Regeneron, all outside the submitted work. From 2012-2020 she acted as Director Respiratory & Allergy Research at QPS-Netherlands; in 2019-ongoing, QPS-Netherlands received a European grant from ERA4TB (4 years)and funding from Foresee Pharmaceuticals for early respiratory studies.
Philippe Gevaert: Has participated in advisory boards and received spea­ker fees from ALK-Abelló, Argenx, AstraZeneca, Genentech, GSK, Novartis, Regeneron, Roche, Sanofi Genzyme, and Stallergenes- Greer.
Joseph Han: Research consultant for Sanofi, Regeneron, GlaxoSmithKline, and
AstraZeneca.
Enrico Heffler: Speaker’s fee and Advisory Board participation for: Sanofi; Regeneron; GSK; Astrazeneca; Novartis; Chiesi; Stallergenes-Greer; Almirall; Bosch.
Claire Hopkins: Ad boards – GSK, Sanofi Regeneron, Lilly.
Basile Landis: No conflicts of interest to declare in relation to this initiative.
Olga Lourenco: No conflicts of interest to declare in relation to this initiative.
Valerie Lund: Honoraria for speaking and advisory boards: Abbot, Alcimed, Evidera, GRG, GSK, Novartis, Sanofi. Editor, Cummings Otorhinolaryngology, Elsevier.
Amber Luong: Consultant or member of scientific advisory boards for ENTvantage Dx, Lyra Therapeutics, Maxwell Biosciences, Medtronic, Sanofi, SoundHealth, and Stryker.
Joaquim Mullol: Joaquim Mullol is or has been member of national and international scientific advisory boards, consulting, received fees for lectures, and grants for research projects or clinical trials from AstraZeneca, Genentech-Roche, GSK, LETI, Lilly, Menarini, MSD, Mitsubishi-Tanabe, NOUCOR/Uriach Group, Novartis, OPTINOSE, Proctor & Gamble, Regeneron Pharmaceuticals Inc., Sanofi-Genzyme, UCB Pharma, and Viatris/MEDA Pharma.
Anju Peters: Received fee for consultation and advisory board by Sanofi Regeneron, GSK, AstraZeneca, Merck, and Optinose. Research support to the institution by Sanofi Regeneron, Merck, and AstraZeneca.
Carlo Philpott: Horararia for speaker/advisory boards: GSK, Sanofi, Olympus, Abbott, Stryker. Grants from NIHR. Trustee of Fifth Sense.
Sietze Reitsma: Has acted as a consultant and/or advisory board member for Sanofi, GSK, and Novartis. The department of Otorhinolaryngology and Head/Neck Surgery of the Amsterdam UMC has received research funding from Sanofi, GSK, and Novartis.
Dermot Ryan: No conflicts of interest to declare in relation to this initiative.
Glenis Scadding: Honoraria for articles, speaker and advisory boards: ALK, Bayer, GlaxoSmithKline, Haleon, Noucor, Sanofi- Regeneron, and Viatris. Chair of BSACI rhinitis guidelines, Scientific Chief Editor, Rhinology Section of Frontiers in Allergy, Board member and AR lead for EUFOREA, and Chair/ member Data Monitoring Committees on SLIT for ALK.
Brent Senior: Lyra Therapeutics: consultant, Stryker: Consultant, Neurent: consultant, MCSP: consultant and American Rhinologic Society: VP of Development and Strategy.
Valentin Tomazic: No conflicts of interest to declare in relation to this initiative.
Elina Toskala:   Consultation fees and research grants: GSK, Sanofi, Aerin,
Optinose, Medtronic.
Thibaut Van Zele: Honararia for consultancy and courses for Medtronic.
An-Sofie Viskens: No conflicts of interest to declare in relation to this initiative.
Martin Wagenmann: Fees for lectures and / or participation in scientific advisory
boards: ALK-Abelló, AstraZeneca, CSL Behring, Genzyme, GSK, Infectopharma,
LETI Pharma, Novartis, Regeneron, Sanofi, Stallergenes. Grants (to institution):
ALK-Abelló, AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi-Aventis,
Takeda.
W. J. Fokkens: The department of Otorhinolaryngology of the Amsterdam University Medical centre, location AMC received grants for research in Rhinology from: ALK, Allergy Therapeutics, Chordate, Novartis, EU, GSK, MYLAN, Sanofi-Aventis, and Zon-MW. Wytske Fokkens received consultation and/or speaker fees from Dianosic, GSK, Novartis and Sanofi-Aventis/ Regeneron and is chair of EPOS and board member of EUFOREA.